Clinical pharmacokinetics and pharmacodynamics of torasemide
- PMID: 9474471
- DOI: 10.2165/00003088-199834010-00001
Clinical pharmacokinetics and pharmacodynamics of torasemide
Abstract
The new loop diuretic torasemide belongs to the pyridine sulfonylurea class. It is well absorbed and yields a bioavailablity of about 80% in healthy individuals, even higher in patients with oedema. This is roughly double that of the 'classical' loop diuretic furosemide (frusemide) [26 to 65%]. Torasemide is highly bound to protein (99%) as is furosemide. The volume of distribution of torasemide was determined as 0.2 L/kg as compared with 0.11 to 0.18 L/kg for furosemide. Torasemide undergoes extensive hepatic metabolism; only 20% of the parent drug is recovered unchanged in the urine. For comparison only 10 to 20% of furosemide undergoes phase II metabolisation (to the glucuronide). In chronic renal failure the renal clearance of torasemide decreased in proportion to the decrease of the patients' glomerular filtration rate, whereas the total plasma clearance (3 times that of the renal clearance) appeared to be independent of renal function. As expected, the renal excretion of torasemide metabolites is significantly retarded in renal disease. The pharmacokinetics of torasemide are significantly influenced by liver disease. Total plasma clearance of torasemide was reduced to about half of that found in the control group, yielding an increase in elimination half-life. A greater than normal fraction of torasemide was recovered in the urine of patients with cirrhosis. In contrast, the kinetics of furosemide appeared to depend more on kidney function than on liver disease. The pharmacodynamics of torasemide are principally the same as those reported from conventional loop diuretics due to their interference with one binding site in the thick ascending limb of Henle's loop, the Na+:K+:2Cl- carrier. The maximum natriuretic effect of all loop diuretics amounts to about 3 mmol Na+/min. Members of this class differ, however, with respect to their intravenous potency or affinity for the receptor, respectively: bumetanide > piretanide > torasemide > furosemide. So far, the only loop diuretic which has been shown to effectively lower high blood pressure is torasemide. This effect occurs at the low dose of 2.5 mg/day.
Similar articles
-
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.J Hepatol. 1996 Oct;25(4):481-90. doi: 10.1016/s0168-8278(96)80207-8. J Hepatol. 1996. PMID: 8912147 Clinical Trial.
-
Clinical pharmacology of loop diuretics.Drugs. 1991;41 Suppl 3:14-22. doi: 10.2165/00003495-199100413-00004. Drugs. 1991. PMID: 1712712 Review.
-
The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics.Drugs. 1991;41 Suppl 3:23-34. doi: 10.2165/00003495-199100413-00005. Drugs. 1991. PMID: 1712713 Review.
-
Pharmacokinetics and pharmacodynamics of torasemide in health and disease.J Cardiovasc Pharmacol. 1993;22 Suppl 3:S24-31. doi: 10.1097/00005344-199322003-00004. J Cardiovasc Pharmacol. 1993. PMID: 7506334 Review.
-
Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.Arzneimittelforschung. 1988 Jan;38(1A):160-3. Arzneimittelforschung. 1988. PMID: 3370062 Clinical Trial.
Cited by
-
Torasemide prolonged release.Drugs. 2009 Jul 9;69(10):1363-72. doi: 10.2165/00003495-200969100-00006. Drugs. 2009. PMID: 19583454 Review.
-
Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.Sci Rep. 2018 Jun 29;8(1):9877. doi: 10.1038/s41598-018-27995-w. Sci Rep. 2018. PMID: 29959396 Free PMC article.
-
Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.Br J Pharmacol. 2008 Dec;155(7):1066-75. doi: 10.1038/bjp.2008.343. Epub 2008 Aug 25. Br J Pharmacol. 2008. PMID: 18724382 Free PMC article.
-
Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and β-blockers - drug classes with low adherence in antihypertensive therapy.Sci Rep. 2019 Oct 30;9(1):15652. doi: 10.1038/s41598-019-52164-y. Sci Rep. 2019. PMID: 31666620 Free PMC article.
-
Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses.J Vet Intern Med. 2018 Jul;32(4):1428-1435. doi: 10.1111/jvim.15213. Epub 2018 May 17. J Vet Intern Med. 2018. PMID: 29770976 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials